Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 9/2013

01-09-2013 | Translational Research and Biomarkers

XB130 as an Independent Prognostic Factor in Human Esophageal Squamous Cell Carcinoma

Authors: Atsushi Shiozaki, MD, PhD, Toshiyuki Kosuga, MD, Daisuke Ichikawa, MD, PhD, Shuhei Komatsu, MD, PhD, Hitoshi Fujiwara, MD, PhD, Kazuma Okamoto, MD, PhD, Daisuke Iitaka, MD, Shingo Nakashima, MD, Hiroki Shimizu, MD, Takeshi Ishimoto, MD, Maki Kitagawa, MD, Yoshito Nakou, MD, Mitsuo Kishimoto, MD, PhD, Mingyao Liu, MD, Eigo Otsuji, MD, PhD

Published in: Annals of Surgical Oncology | Issue 9/2013

Login to get access

Abstract

Background

Adaptor proteins, with multimodular structures, can participate in the regulation of various cellular functions. A novel adaptor protein XB130 has been implicated as a substrate and regulator of tyrosine kinase-mediated signaling and in controlling cell proliferation and apoptosis in thyroid and lung cancer cells. However, its expression and role in gastrointestinal cancer have not been investigated. We sought to determine the role of XB130 in cell cycle progression of esophageal squamous cell carcinoma (ESCC) cells and to examine its expression and effects on the prognosis of patients with ESCC.

Methods

Expression of XB130 in human ESCC cell lines was analyzed by Western blot testing and immunofluorescent staining. Knockdown experiments with XB130 small interfering RNA (siRNA) were conducted, and the effect on cell cycle progression was analyzed. Immunohistochemistry of XB130 for 52 primary tumor samples obtained from patients with ESCC undergoing esophagectomy was performed.

Results

XB130 was highly expressed in TE2, TE5, and TE9 cells. In these cells, knockdown of XB130 with siRNA inhibited G1–S phase progression and increased the expression of p21, the cyclin-dependent kinase inhibitor. Immunohistochemistry showed that 71.2 % of the patients expressed XB130 in the nuclei and/or cytoplasm of the ESCC cells. Further, nuclear expression of XB130 was an independent prognostic factor of postoperative survival.

Conclusions

These observations suggest that the expression of XB130 in ESCC cells may affect cell cycle progression and impact prognosis of patients with ESCC. A deeper understanding of XB130 as a mediator and/or biomarker in ESCC is needed.
Appendix
Available only for authorised users
Literature
1.
2.
Csiszar A. Structural and functional diversity of adaptor proteins involved in tyrosine kinase signalling. Bioessays. 2006;28:465–79.PubMedCrossRef
3.
Dorfleutner A, Stehlik C, Zhang J, et al. AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells. J Cell Physiol. 2007;213:740–9.PubMedCrossRef
4.
Zhang J, Park SI, Artime MC, et al. AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest. 2007;117:2962–73.PubMedCrossRef
5.
Seals DF, Azucena EF Jr, Pass I, et al. The adaptor protein Tks5/fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell. 2005;7:155–65.PubMedCrossRef
6.
Blouw B, Seals DF, Pass I, et al. A role for the podosome/invadopodia scaffold protein Tks5 in tumor growth in vivo. Eur J Cell Biol. 2008;87:555–67.PubMedCrossRef
7.
Lodyga M, Bai XH, Mourgeon E, et al. Molecular cloning of actin filament-associated protein: a putative adaptor in stretch-induced Src activation. Am J Physiol Lung Cell Mol Physiol. 2002;283:L265–74.PubMed
8.
Han B, Bai XH, Lodyga M, et al. Conversion of mechanical force into biochemical signaling. J Biol Chem. 2004;279:54793–801.PubMedCrossRef
9.
Xu J, Bai XH, Lodyga M, et al. XB130, a novel adaptor protein for signal transduction. J Biol Chem. 2007;282:16401–12.PubMedCrossRef
10.
Shiozaki A, Liu M. Roles of XB130, a novel adaptor protein, in cancer. J Clin Bioinforma. 2011;1:10.PubMedCrossRef
11.
Lodyga M, De Falco V, Bai XH, et al. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. Oncogene. 2009;28:937–49.PubMedCrossRef
12.
Shiozaki A, Lodyga M, Bai XH, et al. XB130, a novel adaptor protein, promotes thyroid tumor growth. Am J Pathol. 2011;178:391–401.PubMedCrossRef
13.
Lodyga M, Bai XH, Kapus A, et al. Novel adaptor protein XB130 is a Rac-controlled component of lamellipodia, which regulates cell motility and invasion. J Cell Sci. 2010;123:4156–69.PubMedCrossRef
14.
Nishihira T, Hashimoto Y, Katayama M, et al. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol. 1993;119:441–9.PubMedCrossRef
15.
Shimada Y, Imamura M, Wagata T, et al. Characterization of 21 newly established esophageal cancer cell lines. Cancer. 1992;69:277–84.PubMedCrossRef
16.
Mura M, Han B, Andrade CF, et al. The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival. Crit Care. 2006;10:R130.PubMedCrossRef
17.
Shiozaki A, Yamagishi H, Itoi H, et al. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer. Oncol Rep. 2005;13:667–72.PubMed
18.
Sobin L, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumors. 7th ed. Hoboken: Wiley, 2009.
19.
Tachibana M, Kinugasa S, Yoshimura H, et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg. 2005;189:98–109.PubMedCrossRef
20.
Ozawa S, Tachimori Y, Baba H, et al. Comprehensive registry of esophageal cancer in Japan, 2003. Esophagus. 2011;8:9–29.CrossRef
21.
Cunha IW, Carvalho KC, Martins WK, et al. Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol. 2010;3:23–32.PubMedCrossRef
22.
DeNardi FG, Riddle RH. Esophagus. In: Sternberg SS, editor. Histology for pathologists. 2nd ed. New York: Raven Press; 1997. p. 461–80.
23.
Islas S, Vega J, Ponce L, et al. Nuclear localization of the tight junction protein ZO-2 in epithelial cells. Exp Cell Res. 2002;274:138–48.PubMedCrossRef
24.
Gottardi CJ, Arpin M, Fanning AS, et al. The junction-associated protein, zonula occludens-1, localizes to the nucleus before the maturation and during the remodeling of cell–cell contacts. Proc Natl Acad Sci USA. 1996;93:10779–84.PubMedCrossRef
25.
Dhawan P, Singh AB, Deane NG, et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest. 2005;115:1765–76.PubMedCrossRef
26.
Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006;5:997–1014.PubMedCrossRef
27.
Takeda K, Kinoshita I, Shimizu Y, et al. Clinicopathological significance of expression of p-c-Jun, TCF4 and beta-catenin in colorectal tumors. BMC Cancer. 2008;8:328.PubMedCrossRef
28.
Liu J, Hu Y, Hu W, et al. Expression and prognostic relevance of p21WAF1 in stage III esophageal squamous cell carcinoma. Dis Esophagus. 2012;25:67–71.PubMedCrossRef
29.
Goan YG, Hsu HK, Chang HC, et al. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients. Ann Thorac Surg. 2005;80:1007–16.PubMedCrossRef
Metadata
Title
XB130 as an Independent Prognostic Factor in Human Esophageal Squamous Cell Carcinoma
Authors
Atsushi Shiozaki, MD, PhD
Toshiyuki Kosuga, MD
Daisuke Ichikawa, MD, PhD
Shuhei Komatsu, MD, PhD
Hitoshi Fujiwara, MD, PhD
Kazuma Okamoto, MD, PhD
Daisuke Iitaka, MD
Shingo Nakashima, MD
Hiroki Shimizu, MD
Takeshi Ishimoto, MD
Maki Kitagawa, MD
Yoshito Nakou, MD
Mitsuo Kishimoto, MD, PhD
Mingyao Liu, MD
Eigo Otsuji, MD, PhD
Publication date
01-09-2013
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 9/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2474-4

Other articles of this Issue 9/2013

Annals of Surgical Oncology 9/2013 Go to the issue

Thoracic Oncology

REG1A Expression Status Suggests Chemosensitivity Among Advanced Thoracic Esophageal Squamous Cell Carcinoma Patients Treated with Esophagectomy Followed by Adjuvant Chemotherapy

Colorectal Cancer

Preoperative Plasma Hyperfibrinogenemia is Predictive of Poor Prognosis in Patients with Nonmetastatic Colon Cancer

Hepatobiliary Tumors

Conversion to Complete Resection and/or Ablation Using Hepatic Artery Infusional Chemotherapy in Patients with Unresectable Liver Metastases from Colorectal Cancer: A Decade of Experience at a Single Institution

Head and Neck Oncology

Thyroid Nodules with Bethesda System III Cytology: Can Ultrasonography Guide the Next Step?

Melanomas

Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma

Head and Neck Oncology

Outcomes and Prognostic Factors of Post-irradiation and de novo Sarcomas of the Head and Neck: A Histologically Matched Case-Control Study